Fable Therapeutics develops biologics for metabolic diseases, focusing on obesity and related co-morbidities. The company utilizes a machine learning-guided protein design platform to rapidly engineer enhanced therapeutics. This computational approach unlocks challenging targets to create novel, best-in-class treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods are inefficient and time-consuming, often relying on serendipitous findings and extensive trial-and-error. Identifying and optimizing protein-based therapeutics is particularly challenging due to the complex relationship between amino acid sequences, protein structure, and biological function.
Solution
Fable Therapeutics is developing a machine learning-driven platform for the rational design of protein-based therapeutics. By mapping the rules that govern how amino acid sequences determine protein structure and function, the platform enables the creation of novel biomedicines with enhanced therapeutic potential. The company's approach leverages advanced computational and AI techniques to overcome the limitations of traditional drug discovery, allowing for the design of programmable proteins with specific properties and functions. This enables the creation of targeted therapies with improved efficacy and reduced off-target effects.
Target Audience
Fable Therapeutics' primary customers are pharmaceutical companies and research institutions seeking to accelerate drug discovery and develop novel protein-based therapeutics.
Features
- Machine learning-driven protein design platform
- Mapping of amino acid sequence to protein structure and function
- Rational design of programmable protein-based therapeutics
- Advanced computational and AI techniques